title: Effects of sufentanil on the release and metabolism of dopamine and ascorbic acid and glutamate release in the striatum of freely moving rats.
abstract: The effects of either intraperitoneally (i.p.) or intrastriatally administered sufentanil on the release and metabolism of dopamine (DA) in the rat striatum were evaluated using in vivo microdialysis. Dialysate concentrations of DA and its acidic metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were increased following i.p. administration of either clinical anesthetic (20 microg/kg) or clinical analgesic (1 microg/kg) sufentanil doses. In addition, sufentanil also increased uric acid concentrations. In contrast, dialysate ascorbic acid and glutamate concentrations were unaffected. Intrastriatal infusion of sufentanil (250 nM) induced only a short lasting decrease in dialysate DA. Subcutaneous naloxone (1.0 mg/kg) abolished sufentanil-induced increases in dialysate DA, DOPAC+HVA and uric acid; however, naloxone (0.1 mM) failed to affect these increases when infused intrastriatally. These results demonstrate that sufentanil, at clinical doses, increases striatal DA release and oxidative metabolism of both DA and xanthine acting at extrastriatal sites with a mu-receptor-mediated mechanism.
authors.affiliation: Department of Pharmacology, University of Sassari, viale S Pietro 43B, 07100 Sassari, Italy.
authors.forename: Pier Andrea
authors.initials: PA
authors.lastname: Serra
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Susini
authors.forename: Gaia
authors.initials: G
authors.lastname: Rocchitta
authors.forename: Rossana
authors.initials: R
authors.lastname: Migheli
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Dessanti
authors.forename: Egidio
authors.initials: E
authors.lastname: Miele
authors.forename: Maria Speranza
authors.initials: MS
authors.lastname: Desole
authors.forename: Maddalena
authors.initials: M
authors.lastname: Miele
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis / Q000378:metabolism; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001205:Ascorbic Acid / Q000032:analysis / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D018698:Glutamic Acid / Q000032:analysis / Q000378:metabolism*; D006719:Homovanillic Acid / Q000032:analysis / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D008297:Male; D017551:Microdialysis; D009068:Movement; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017409:Sufentanil / Q000008:administration & dosage / Q000494:pharmacology*; D014527:Uric Acid / Q000032:analysis / Q000378:metabolism
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D015102:3,4-Dihydroxyphenylacetic Acid; D014527:Uric Acid; D009270:Naloxone; D018698:Glutamic Acid; D017409:Sufentanil; D001205:Ascorbic Acid; D004298:Dopamine; D006719:Homovanillic Acid